期刊
CLINICAL CANCER RESEARCH
卷 28, 期 18, 页码 4146-4157出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-22-0400
关键词
-
类别
资金
- NIH [R35 CA220500, R01 219006]
- Department of Defense [PR120935]
- Alex's Lemonade Stand Reach Award
- Giulio D'Angio Endowed Chair
This study investigated the safety and antitumor activity of [At-211]MABG in neuroblastoma, and found that it has significant survival advantage and can effectively eradicate microscopic residual disease. An alpha particle emitting radiopharmaceutical may be effective against disseminated disease.
Purpose: [I-131]meta-iodobenzylguanidine ([I-131]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [At-211]meta-astatobenzylguanidine ([At-211] MABG) is an alpha particle emitter with higher biological effective-ness and short path length which effectively sterilizes microscopic residual disease. Here we investigated the safety and antitumor activity [At-211]MABG in preclinical models of neuroblastoma. Experimental Design: We defined the maximum tolerated dose (MTD), biodistribution, and toxicity of [At-211]MABG in immuno-deficient mice in comparison with [I-131]MIBG. We compared the antitumor efficacy of [At-211]MABG with [I-131]MIBG in three murine xenograft models. Finally, we explored the efficacy of [At-211]MABG after tail vein xenografting designed to model disseminated neuroblastoma. Results: The MTD of [At-211]MABG was 66.7 MBq/kg (1.8 mCi/kg) in CB17SC scid(-/-) mice and 51.8 MBq/kg (1.4 mCi/kg)in NOD.Cg-Prkdc(scid) Il2rgt(m1Wjl)/SzJ (NSG) mice. Biodistribution of [At-211]MABG was similar to [I-131]MIBG. Long-term toxicity studies on mice administered with doses up to 41.5 MBq/ kg (1.12 mCi/kg) showed the radiotherapeutic to be well tolerated. Both 66.7 MBq/kg (1.8 mCi/kg) single dose and fractionated dosing 16.6 MBq/kg/fraction (0.45 mCi/kg) x 4 over 11 days induced marked tumor regression in two of the three models studied. Survival was significantly prolonged for mice treated with 12.9 MBq/kg/fraction (0.35 mCi/kg) x 4 doses over 11 days [At-211]MABG in the disseminated disease (IMR-05(NET/GFP/LUC)) model (P = 0.003) suggesting eradication of microscopic disease. Conclusions: [At-211]MABG has significant survival ad-vantage in disseminated models of neuroblastoma. An alpha particle emitting radiopharmaceutical may be effective against microscopic disseminated disease, warranting clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据